06/12/2018 15:14:14

Beyond Celiac partners with imaware™ to expand use of at-home celiac disease testing for faster medical diagnosis

Philadelphia, PA, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Beyond Celiac today announced their newest partner, imaware™.  imaware™ is a unique at-home celiac disease screening and monitoring test that is highly accurate and provides actionable results for patients. Beyond Celiac is partnering with imaware™ to support the ambitious goal of dramatically reducing the number of individuals dealing with undiagnosed celiac disease by helping them more quickly take the steps needed for diagnosis.

“Celiac disease has long been plagued by low diagnosis rates. It is estimated that less than 20 percent of patients who have the condition know it,” noted Alice Bast, Beyond Celiac CEO. “We hear from our community that their doctors do not want to test them despite symptoms. The average delay in diagnosis is 6 to 10 years. It took me eight years to get diagnosed,” she added.

A study published recently in the United European Gastroenterology Journal concluded that patients whose diagnosis had been delayed for three years reported being sick more often, going to the doctor more frequently and using more drugs for indigestion and depression than those who were diagnosed more quickly.

“We believe that the imaware™ at-home celiac disease test will help reduce the number of undiagnosed people with celiac disease,” said Jani Tuomi, Chief Product Officer for imaware™. “An easy to use test, with easy to read results that are reviewed by a doctor, will dramatically reduce time to diagnosis. With a partner like Beyond Celiac, we will be able to better engage with the patient community to educate, screen, and ultimately help patients engage their doctors sooner for diagnosis.”

The imaware™ test measures the same antibodies to gluten as the tests that doctors use in their offices as the first step to diagnose celiac disease – anti-tissue transglutaminase (tTG) and deaminated gliadin peptide (DGP) tests. In the United States, definitive diagnosis of celiac disease requires a biopsy that shows intestinal damage in addition to the blood test.

Sold online only, the imaware™ test requires a finger prick and collection of a small amount of blood in a vial. Consumers then mail their sample back and receive their confidential test results via a secure portal in about a week. For results to be accurate, consumers need to be on a normal gluten-containing diet. The imaware™ at-home test for celiac disease is available at imaware.health for $165.00. Beyond Celiac will receive a portion of sales to support their ongoing initiatives to drive diagnosis, advance research and accelerate the discovery of new treatments and a cure. 


About Celiac Disease

Celiac disease is a serious, genetic, autoimmune disorder that affects an estimated 1 in 100 Americans, the vast majority of whom are still undiagnosed. The disease causes debilitating symptoms, and if left untreated, can lead to serious long-term health problems including infertility and some types of cancer.

About Beyond Celiac:

A 501(c)(3) non-profit organization, Beyond Celiac envisions a world in which people with celiac disease can live healthy lives free from social stigma and fear of gluten exposure – A world Beyond Celiac.


Claire Baker

Beyond Celiac

215-325-1306 ext. 111



Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Mar
Hejsa Lidt forårs opdatering. Langsigtet konjunkturmodel: Nederst kan I se den langsigtede konjunktu..
18 Mar
SAS's emmision overtegnet så de regner med 15MUSD i provenu samlet - godt nyt for GOMSpace hvis de k..
14 Mar
Elliot.Blot for info så har jeg cirka 14.000 timer på 737 serien og der er altid problemer når en ty..
19 Mar
  Studiet er et randomiseret fase 4 forsøg, hvor man sammenligner forlænget frigivelse Envarsus XR (..
14 Mar
Danske Bank er sværd at værdiansætte set i forhold til den situation som Danske Bank befinder sig i...
13 Mar
Der er nogle enkelt punkter som jeg har noteret mig under læsningen af Årsrapporten 2018 samt de sen..
Jeg skrev til IR vedr. lidt forskelligt, her er deres svar:  Bliver der afholdt en Capital Market D..
18 Mar
For mig virker det ret underligt at udmelding fra FDA om ydereligere 3mdr mere behandlingstid bliver..
15 Mar
Det forhold, at Pandora på trods af negativ analyse fra Carnegie og udbetaling af udbytte har holdt ..
19 Mar
Siden topformationen i 23 området har trenden krydset flere støttelinjer og er nu ved en mulig dobbe..


EuroInvestor: In Focus


EuroInvestor: In Focus


EuroInvestor: In Focus

Most read news

  • 24 hours
  • 48 hours
  • 1 week
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Health Insurance, Conagra, Kraft Heinz, and Diplomat and Encourages Investors to Contact the Firm
PDAC welcomes Federal Budget 2019
PureCircle Launches Next Generation Stevia Leaf Sweeteners in Singapore
NanoString Technologies Announces Pricing of Public Offering of 4,500,000 Shares of Common Stock
Dermira Prices $130.0 Million Public Offering of Common Stock

Latest news

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
20 March 2019 20:07:24
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190320.1 - EUROWEB1 - 2019-03-20 21:07:24 - 2019-03-20 20:07:24 - 1000 - Website: OKAY